TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01404299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: - Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: - No intervention, except monthly home visits
Study: NCT00003793

Intervention type: GENETIC
Intervention: clonality analysis

Intervention type: GENETIC
Intervention: microsatellite instability analysis

Intervention type: GENETIC
Intervention: microsatellite instability analysis

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: mutation analysis
Study: NCT03164382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Firstly, the femoral artery was percutaneously punctured using the Seldinger technique. Then, the catheter was inserted into the celiac trunk or superior mesenteric artery for arteriography. When more than one feeding artery of HCC was detected, the smaller arteries were embolized with gelatin sponge particles. A micro-catheter was inserted through the arterial catheter located at the common hepatic artery or proper hepatic arterial branch (feeding artery). When blood flows into the gastroduodenal artery was confirmed by micro-catheter angiography, the route was embolized with a coil or micro-coil to prevent reflux of chemotherapeutic drugs to the stomach and duodenum. The peripheral part of the catheter that was exposed to the outside of the body was covered with medical sterile gauze and fastened on the thigh's skin using medical rubberized fabric and bandage. Catheter insertion was repeatedly performed before every cycle of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib 200Mg Tab
Description: Sorafenib will be administered orally at the starting dose of 400 mg twice daily (800 mg total daily dose) to patients randomized to Arm S in accordance to its package insert or equivalent documentation. The 400 mg dose will be achieved by administration of 2 x 200 mg film-coated tablets, administered twice daily.
Study: NCT00133523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold-adapted live attenuated influenza virus vaccine, trivalent
Description: Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline administered as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal allantoic fluid administered annually as an internasal spray.
Study: NCT03833830

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography angiography (OCTA)
Description: There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group \>20 injections and shortterm treatment group \< 5 injections).

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography angiography (OCTA)
Description: There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group \>20 injections and shortterm treatment group \< 5 injections).
Study: NCT06423079

Intervention type: PROCEDURE
Intervention: Siepser knots
Description: Surgical intervention involved creating a superior service keratotomy and using introflective sutures for IOL fixation
Study: NCT04703894

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES 'CARDIFF'
Description: AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
Study: NCT02083380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel 800mg: piperaquine 640mg
Description: Active, loose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel 800mg: piperaquine 960mg
Description: Active, loose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel 800mg: piperaquine 1440mg
Description: Active, loose combination
Study: NCT01164085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Ketorolac
Description: 4mg of intravitreal ketorolac
Study: NCT04514679

Intervention type: BEHAVIORAL
Intervention: Healthy Lifestyles Program
Description: Regular group visits with a health coach in addition to routine dietician and clinician visits, reviewing successes and challenges from the previous session as well as data collected through self-monitoring

Intervention type: BEHAVIORAL
Intervention: Obesity Medicine Program
Description: A tailored approach to obesity care for patients including individual dietician and health coach visits as appropriate.
Study: NCT01964066

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography balloon dilatation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography balloon dilatation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Description: Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Premedication
Description: For premedication used trimeperidine 2%-1ml intravenously.
Study: NCT00522795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPX with cisplatin and radiation
Description: weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
Study: NCT02690623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric hospitalist program
Description: In-house hospitalists available at all hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Pediatric Inpatient Services
Description: Inpatient care by general pediatrics faculty
Study: NCT04276584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive expiratory pressure
Description: Three blocks of 10 deep inspiration followed by expiration against a positive airway pressure device of 10-15 cm of water pressure. Repeated three times. Estimated time of 3 minutes time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speaking loudly during about 3 minutes
Description: A specified swedish text
Study: NCT01044966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITV DepoCyt + Temozolomide
Description: Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
Study: NCT03783520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG Laser
Description: Er,Cr:YSGG Laser is used for disinfection of the root canals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: Sodium hypochlorite is used for disinfection of the root canals
Study: NCT02771132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-hr IMPower empowerment self defense course
Description: The purpose of the 12-hr IMPower empowerment self defense course intervention for girls is to empower then to avoid risky situations, advocate for themselves, and, if needed, defend themselves against an attack.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-hr Source of Strength for boys
Description: The 12-hr Source of Strength for boys curriculum is specifically designed for 10-13 year-old boys and focused on promoting gender equality, developing positive masculinity, and teaching safe and effective bystander intervention techniques.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life-skills course
Description: A 1.5-2 hour life skills class that is based on the Kenyan Ministry of Education life skills course and includes a wide range of topics, including sexual assault but also sanitation, food safety, and personal rights. All school-aged children who attend school typically receive this type of curriculum.
Study: NCT03771365

Intervention type: PROCEDURE
Intervention: Standard-PCNL
Description: percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone

Intervention type: PROCEDURE
Intervention: Mini-PCNL
Description: percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone

Intervention type: PROCEDURE
Intervention: SMP
Description: percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone
Study: NCT04111029

Intervention type: DIAGNOSTIC_TEST
Intervention: Cell Free DNA
Description: Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy
Study: NCT03959280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Description: * The exercise program consists of 2 x 1.5-hour supervised nordic walking sessions weekly during 12 weeks and 1-hour unsupervised moderate physical activity per week from week 4.~* The diet intervention includes one face-to-face consultation with a dietician and one telephone-based contact monthly, i.e. 6 diet interventions for 12 weeks.~* Behavioural changes techniques will be included in diet and exercise interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This intervention will include tailored instruction on CPAP use and standard advices on physical activity and nutrition at CPAP initiation.
Study: NCT02163018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAL-MPE1
Description: Subcutaneous administration of increasing doses of HAL-MPE1
Study: NCT02735135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENTRY 1200 for 1 month
Description: The patient is placed on a SENTRY 1200 mattress for 1 month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENTRY 1200 for 1 day
Description: The patient is placed on a SENTRY 1200 mattress for 1 day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIRSOFT DUO for 1 month
Description: The patient is placed on an AIRSOFT DUO mattress for 1 month.
Study: NCT01542567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abitren
Description: SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suppositories
Study: NCT00802113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 x 5 days
Study: NCT02163018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration of increasing doses of placebo
Study: NCT03529292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmeaCell
Description: Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
Study: NCT01022190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib (Arcoxia)
Description: Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
Study: NCT03979092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-ACLS
Description: Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~1. Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~2. Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~3. Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~4. Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: Waitlist group will participate in subsequent IP-ACLS training.
Study: NCT01903837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan (Low Dose)
Description: Tablets taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan (Medium Dose)
Description: Tablets taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan (High Dose)
Description: Tablets taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Tablets taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Tablets taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Tablets taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Tablets taken once daily
Study: NCT00835471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib plus docetaxel or pemetrexed
Description: non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib 150 mg/day continuously until disease progression
Study: NCT00244023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
Study: NCT03413020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bismuth Potassium Citrate
Description: gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: antibiotic for H. pylori eradication
Study: NCT02011009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV seropositive patients
Description: During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
Study: NCT01937650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy plus metronidazole
Description: Metronidazole was added to the standard radiotherapy that is routinely used.
Study: NCT02595190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral canal cyst microscopic tamponade
Description: sacral canal cyst microscopic tamponade treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin + tramadol
Description: dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: resting state functional magnetic resonance imaging (rfMRI)
Description: First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resting state functional magnetic resonance imaging (rfMRI)
Description: First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resting state functional magnetic resonance imaging (rfMRI)
Description: First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
Study: NCT00802113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg/day x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg/day x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
Study: NCT03663400

Intervention type: DIAGNOSTIC_TEST
Intervention: GWAS analysis by Illumina BeadChip
Description: will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
Study: NCT03354507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate. See arms.
Study: NCT02280798

Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: 4 endometrial biopsy
Study: NCT02062658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg IV

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
Study: NCT02164422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine 3mg/day
Description: 3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine 1.5mg/day
Description: 1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00857870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of \<5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
Study: NCT00271323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
Study: NCT01061450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 80 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill once a day